ProQR

ProQR was founded in 2012 by chief executive officer Daniel de Boer and co-founders Henri Termeer, Dinko Valerio and Gerard Platenburg.The initial pipeline of the company was to develop small-molecule drugs or gene therapy that would treat cystic fibrosis . Positive proof of concept was achieved in 2016 with the clinical trial of the molecule QR-010 targeting the gene coding for cystic fibrosis transmembrane conductance regulator in patients. Subsequently, the company expanded its pipeline into treating other rare diseases.In 2017, a spin-out of ProQR named Amylon Therapeutics was established in Leiden with the focus on the development of therapies for the central nervous system.In 2021, ProQR announced a collaboration with Eli Lilly and Company on the Axiomer technology focused on "genetic disorders in the liver and nervous system". They signed a deal with which ProQR would receive $50 million and an equity investment of $30 million. The relationship between the two firms "deepened" in 2022 with expansion of the indications engagement and a $75 million cash infusion which included an equity stake.